Table 2.
Market share and absolute number of patients receiving BoNT-A
| Scenarios | BoNT-A treatment | Year 1
|
Year 2
|
Year 3
|
Year 4
|
Year 5
|
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Proportion of patients eligible (%) | Number of patients eligible | Proportion of patients eligible (%) | Number of patients eligible | Proportion of patients eligible (%) | Number of patients eligible | Proportion of patients eligible (%) | Number of patients eligible | Proportion of patients eligible (%) | Number of patients eligible | ||
| Status quo | AbobotulinumtoxinA | 69 | 7,525 | 69 | 7,601 | 69 | 7,678 | 69 | 7,756 | 69 | 7,834 |
| OnabotulinumtoxinA | 15.5 | 1,690 | 15.5 | 1,708 | 15.5 | 1,725 | 15.5 | 1,742 | 15.5 | 1,760 | |
| IncobotulinumtoxinA | 15.5 | 1,690 | 15.5 | 1,708 | 15.5 | 1,725 | 15.5 | 1,742 | 15.5 | 1,760 | |
| Total | 100 | 10,906 | 100 | 11,016 | 100 | 11,128 | 100 | 11,240 | 100 | 11,353 | |
| New projections | AbobotulinumtoxinA | 69 | 7,525 | 72 | 7,932 | 75 | 8,346 | 78 | 8,767 | 81 | 9,196 |
| OnabotulinumtoxinA | 15.5 | 1,690 | 14 | 1,542 | 12.5 | 1,391 | 11 | 1,236 | 9.5 | 1,079 | |
| IncobotulinumtoxinA | 15.5 | 1,690 | 14 | 1,542 | 12.5 | 1,391 | 11 | 1,236 | 9.5 | 1,079 | |
| Total | 100 | 10,906 | 100 | 11,016 | 100 | 11,128 | 100 | 11,240 | 100 | 11,353 | |
Abbreviation: BoNT-A, botulinum neurotoxin A.